Current Gastroenterology Reports最新文献_第7页

Is Eosinophilic Colitis a Forerunner of Inflammatory Bowel Disease? 嗜酸性结肠炎是炎症性肠病的先兆吗？

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-08-11 DOI: 10.1007/s11894-025-01009-y

P Thirumal, Seetharaman Keerthivasan, Kuppusamy Senthamizhselvan

{"title":"Is Eosinophilic Colitis a Forerunner of Inflammatory Bowel Disease?","authors":"P Thirumal, Seetharaman Keerthivasan, Kuppusamy Senthamizhselvan","doi":"10.1007/s11894-025-01009-y","DOIUrl":"10.1007/s11894-025-01009-y","url":null,"abstract":"Purpose of review: Eosinophilic colitis (EoC) has an increasing association with inflammatory bowel disease (IBD), and there is a paucity of data on the natural history of EoC. Here, we provide a comprehensive overview of EoC and critically evaluate the evidence supporting its potential association with, or evolution into IBD.Recent findings: Experts currently classify EoC as one of the eosinophilic gastrointestinal disorders (EGID) beyond eosinophilic esophagitis (EoE). Transcriptomic analyses have demonstrated a distinct molecular signature for EoC. However, recent studies suggest that a subset of patients with EoC may progress to develop IBD. The key predictive factors include high eosinophilic density on colonic biopsy and poor response or relapse following standard therapy. Emerging evidence suggests that EoC may precede or overlap with IBD. The lack of standardized diagnostic criteria and limited longitudinal data hinder firm conclusions and warrant future prospective multicenter studies. Available current literature suggests that clinicians should be vigilant with persistent or severe symptomatic patients despite standard treatment to evaluate for IBD.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"60"},"PeriodicalIF":4.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Traditional and Novel Colonoscopy Quality Metrics: What's Important in 2025. 传统和新型结肠镜检查质量指标：2025年的重要因素。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-08-08 DOI: 10.1007/s11894-025-01006-1

Carl L Kay, Geoffrey A Bader, Charles B Miller

{"title":"Traditional and Novel Colonoscopy Quality Metrics: What's Important in 2025.","authors":"Carl L Kay, Geoffrey A Bader, Charles B Miller","doi":"10.1007/s11894-025-01006-1","DOIUrl":"10.1007/s11894-025-01006-1","url":null,"abstract":"Purpose of review: This review summarizes current landscape of colonoscopy quality metrics, with an emphasis on priority intraprocedural indicators. We aim to clarify the rationale, evidence, and practical implementation of both traditional and recently introduced metrics-highlighting which measures are most relevant for improving patient outcomes in 2025.Recent findings: The 2024 ACG/ASGE guidelines reaffirmed the core quality indicators of adenoma detection rate (ADR), cecal intubation rate (CIR), bowel preparation adequacy, and guideline-based surveillance interval assignment. The guidelines also introduced new metrics such as sessile serrated lesion detection rate (SSLDR), adenomas per colonoscopy (APC), extended withdrawal time, and a distinct ADR benchmark for colonoscopies following positive fecal screening. Altogether, these updates reflect a shift toward more granular, detection-focused metrics. The traditional quality indicators remain the cornerstone of high colonoscopy quality due to their feasibility in most clinical settings and established correlation with reducing post-colonoscopy colorectal cancer rates (PCCRC). New detection-based metrics, particularly SSLDR and APC, have independent impacts on lowering PCCRC, but unique challenges in becoming widely adopted. We advocate for endoscopists to establish a strong foundation of traditional colonoscopy quality metrics while working towards establishing systems to monitor novel quality metrics like SSLDR and APC. Quality measurement, whether automated or manually tracked, remains the key to delivering high-quality, cancer-preventing colonoscopy.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"58"},"PeriodicalIF":4.1,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital and Conventional Behavioral Therapies for Neurogastroenterology and Motility Disorders. 神经胃肠病学和运动障碍的数字和传统行为疗法。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-08-04 DOI: 10.1007/s11894-025-01007-0

Pooja N Dave, Sarah Kinsinger

{"title":"Digital and Conventional Behavioral Therapies for Neurogastroenterology and Motility Disorders.","authors":"Pooja N Dave, Sarah Kinsinger","doi":"10.1007/s11894-025-01007-0","DOIUrl":"10.1007/s11894-025-01007-0","url":null,"abstract":"Purpose of review: Brain-gut behavior therapies (BGBTs) comprise of several behavioral and psychological therapies such as cognitive-behavioral therapy or gut-directed hypnotherapy that are effective at improving symptom management and quality of life for patients with a range of neurogastroenterology and motility disorders. This review highlights recent advances in BGBT approaches, including novel delivery methods to improve access to care.Recent findings: Traditional BGBT approaches have evolved to more effectively target GI-specific psychological processes, with exposure techniques and mindfulness-based skills emerging as important elements of treatment. BGBTs are also being delivered in new ways, including digital formats, to expand access to care. Digital therapeutics show promise; however, feasibility of these tools in clinical practice remains unclear. BGBTs continue to evolve to address the complex needs of patients with Disorders of Gut-Brain Interaction (DGBI) and are being applied more broadly to treat the full spectrum of DGBI conditions. Novel delivery methods show promise; however, further research is needed to identify real-world effectiveness of digital treatments and to identify patients most likely to benefit.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"57"},"PeriodicalIF":4.1,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update in Inflammatory Bowel Disease Management in the Elderly. 老年炎症性肠病管理的最新进展。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-08-04 DOI: 10.1007/s11894-025-01005-2

Farhad Peerani

引用次数: 0

Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies. 新辅助治疗在胃肠道恶性肿瘤手术入路重塑中的作用。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-30 DOI: 10.1007/s11894-025-01003-4

Daniella Ifeoluwatomiwa Odunsi, Hanna Mohammed Sherief, Shaikha Alhajeri, Kinitoli Rochill, Khadeeja Mahjoor, Gonzalo Navarro, Dalila Marra, Joud Abourdan, Jurgen Baldelomar Ortiz, Ahmad Mahmood Rolse, Manju Rai

{"title":"Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies.","authors":"Daniella Ifeoluwatomiwa Odunsi, Hanna Mohammed Sherief, Shaikha Alhajeri, Kinitoli Rochill, Khadeeja Mahjoor, Gonzalo Navarro, Dalila Marra, Joud Abourdan, Jurgen Baldelomar Ortiz, Ahmad Mahmood Rolse, Manju Rai","doi":"10.1007/s11894-025-01003-4","DOIUrl":"10.1007/s11894-025-01003-4","url":null,"abstract":"Purpose of review: This review explores the evolving role of neoadjuvant therapy (NAT) in the management of gastrointestinal (GI) malignancies, emphasizing its impact on surgical resectability, tumor downstaging, and survival outcomes. It examines how NAT is reshaping traditional surgical approaches across GI cancers.Recent findings: Recent evidence highlights the integration of chemotherapy, radiotherapy, immunotherapy, and targeted therapies in NAT protocols for esophageal, gastric, colorectal, pancreatic, and hepatobiliary cancers. Studies report improved R0 resection rates, reduced lymph node positivity, and enhanced eligibility for organ-preserving procedures. Precision medicine and artificial intelligence are emerging as tools to refine patient selection and predict therapeutic responses. NAT has transformed GI cancer care from a surgery-first model to a multimodal, biology-driven approach. While its benefits are substantial, challenges persist in toxicity management and treatment optimization. Future research should focus on refining protocols, enhancing predictive models, and advancing personalized therapeutic strategies to maximize patient outcomes.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"55"},"PeriodicalIF":4.1,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Barrett's Esophagus in the Context of Achalasia. 贲门失弛缓症患者Barrett食管的治疗。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-28 DOI: 10.1007/s11894-025-00996-2

Margaret J Zhou, John O Clarke

引用次数: 0

Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use? 雷司替米治疗脂肪肝：数据支持广泛使用吗？

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-22 DOI: 10.1007/s11894-025-01002-5

Winston Dunn, Naim Alkhouri

引用次数: 0

Practical Tips for Diagnosis and Management of Concomitant Inflammatory Spondyloarthritis and Inflammatory Bowel Disease. 诊断和治疗伴有炎症性脊柱炎和炎症性肠病的实用技巧。

Current Gastroenterology Reports Pub Date : 2025-07-14 DOI: 10.1007/s11894-025-00990-8

Katherine Falloon, Michael Forney, Shashank Cheemalavagu, M Elaine Husni, Florian Rieder

引用次数: 0

Anti-Reflux Mucosectomy: Our Experience & Thoughts For The Future. 抗反流性粘膜切除术：我们的经验和对未来的思考。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-11 DOI: 10.1007/s11894-025-00992-6

Jean-Christophe N Rwigema, Michael B Ujiki

引用次数: 0

Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives. 粪便微生物群移植治疗肠-脑相互作用疾病：当前的见解，有效性和未来的前景。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-09 DOI: 10.1007/s11894-025-01001-6

Taha Bin Arif, John A Damianos, Asad-Ur- Rahman, Nimra Hasnain

{"title":"Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives.","authors":"Taha Bin Arif, John A Damianos, Asad-Ur- Rahman, Nimra Hasnain","doi":"10.1007/s11894-025-01001-6","DOIUrl":"10.1007/s11894-025-01001-6","url":null,"abstract":"Purpose of review: Dysbiosis can disrupt intestinal barrier integrity and impact the immune and nervous systems, playing a significant role in developing disorders of gut-brain interaction (DGBI). This review aims to provide a comprehensive understanding of dysbiosis and its role in DGBI while examining the latest advancements in fecal microbiota transplantation (FMT). It also highlights key challenges in the field and outlines critical directions for future research to optimize FMT strategies, ultimately improving patient outcomes in this evolving treatment area.Recent findings: In DGBI, dysbiosis triggers immune responses, increases gut permeability, and disrupts nervous system signaling, with contributing factors including diet, antibiotics, stress, and infections. Individuals with DGBI exhibit distinct microbial imbalances, such as an increased Firmicutes-to-Bacteroidetes ratio and reduced beneficial bacteria. FMT has shown mixed results, with factors like patient selection, treatment protocols, and microbiome diversity influencing outcomes. While FMT can improve symptoms in refractory irritable bowel syndrome (IBS), effects may fade over time, requiring repeat treatments. Future FMT approaches should focus on targeted microbial interventions, considering the role of archaea, fungi, and microbial metabolites, while prioritizing optimal donor selection and large-scale trials for long-term efficacy. Despite the promising findings, FMT has not yet been widely endorsed in clinical guidelines due to the variability and heterogeneity of the data available. While much of the research has focused on IBS, studies have also explored the impact of FMT on other conditions such as functional diarrhea, functional constipation, and functional dyspepsia, which all exhibit altered microbial profiles.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"50"},"PeriodicalIF":4.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0